Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome

Proteus syndrome is a life-threatening segmental overgrowth syndrome caused by a mosaic gain-of-function AKT1 variant. There are no effective treatments for Proteus syndrome. Miransertib is an AKT1 inhibitor that, prior to this study, has been evaluated only in adult oncology trials. We designed a n...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Am J Hum Genet
Main Authors: Keppler-Noreuil, Kim M., Sapp, Julie C., Lindhurst, Marjorie J., Darling, Thomas N., Burton-Akright, Jasmine, Bagheri, Mohammadhadi, Dombi, Eva, Gruber, Ashlyn, Jarosinski, Paul F., Martin, Staci, Nathan, Neera, Paul, Scott M., Savage, Ronald E., Wolters, Pamela L., Schwartz, Brian, Widemann, Brigitte C., Biesecker, Leslie G.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6407523/
https://ncbi.nlm.nih.gov/pubmed/30803705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajhg.2019.01.015
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki